Stephen V Liu: ELCC24 Great discussion of Antibody drug conjugates toxicity from Dr. Jarushka Naidoo, noting that each component of the antibody drug conjugate will impact toxicity
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post by Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics Georgetown University, on X:
“Together with improving outcomes for cancer patients, Antibody drug conjugates are creating a new set of challenges pertaining to toxicity prevention and management. Jarushka Naidoo thank you for raising awareness on this critical topic and for citing our recent Nature Reviews Clinical Oncology review!”
Quoting Stephen V Liu‘s post:
“ELCC24 Great discussion of Antibody drug conjugates toxicity from Dr. Jarushka Naidoo, noting that each component of the antibody drug conjugate (target, Ab, linker, payload) will impact toxicity. Good awareness of ILD, which is dose dependent, but many other unique toxicities to watch.”
Source: Paolo Tarantino/X and Stephen V Liu/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023